Please ensure Javascript is enabled for purposes of website accessibility

Why Abiomed Plunged Today

By Brian Feroldi – Nov 12, 2018 at 5:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares tumbled after the company reports good news. Here's what investors need to know.

What happened

Shares of the fast-growing medical device maker Abiomed (ABMD -1.33%) plunged 16% on Monday. The selling pressure appears to have been caused by the release of good-but-not-great clinical data and some tepid commentary from the analyst community. 

So what

Abiomed announced the results of a safety and feasibility study for patients with anterior ST-segment elevation myocardial infarction (STEMI) on Sunday. The company was testing whether it would be safe to use the Impella pump to clear out the left ventricle 30 minutes prior to reperfusion.

The results from the 50-patient study showed that there was no increase in major cardiovascular events for 30 days after emptying the left ventricle ahead of time. In addition, the study also suggested that there may be clinical benefits to doing so.

A male doctor with gloved hands and mask over his mouth, as if preparing for surgery

Image source: Getty Images.

While the data was strong enough to convince Abiomed to move forward with a pivotal trial an analyst at Jefferies released a report to his clients on Monday stating that the report was good but "likely not enough to move the stock."

Since Abiomed's stock has been on fire in 2018 -- shares are up 80% year to date even after including today's drubbing -- it is likely that Wall Street was expecting even better news in the press release and sold in response.

Now what

Abiomed's stock is still very richly priced so it is likely to be volatile whenever major news is released. However, short-term price movements shouldn't scare off long-term investors who are bullish on the company's market opportunity


Brian Feroldi owns shares of Abiomed. The Motley Fool owns shares of and recommends Abiomed. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ABIOMED, Inc. Stock Quote
$245.66 (-1.33%) $-3.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.